Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that a combination of cyproterone acetate and ethinyl estradiol over one year did not affect glucose tolerance but increased total cholesterol, HDL cholesterol, and triglycerides in patients with moderate hyperandrogenism.

This study observed that women using combined oral contraceptives experienced more nausea, vomiting, and hair loss, while those on Depo-Provera were more likely to gain weight.

This article reviews the medical history and symptoms related to hyperandrogenism in patients, but reports no new clinical findings.

This study evaluated the effects of metformin, ethinyl estradiol/cyproterone acetate (EE/SA), and their combination on carotid intima-media thickness and various cardiovascular markers in patients with polycystic ovary syndrome.

This study found that norethindrone and levonorgestrel affected Arabidopsis thaliana root growth differently depending on concentration, with levonorgestrel being highly active and most effective at promoting taproot growth at low doses.

This study found that scabies was the most common skin condition among children up to 15 years old at a Karachi hospital in 2005.

This review examines the epidemiology, pathophysiology, diagnosis, and management strategies for non-classic congenital hyperplasia due to 21-hydroxylase deficiency, and provides evidence-based recommendations for its treatment and genetic counseling.

This study found that ethinylestradiol and high-dose cyproterone acetate significantly reduced hirsutism scores and were effective for treating acne and alopecia in women with hyperandrogenism.

This review discusses developments in oral contraceptives, highlighting improved individualization, reduced side effects, and enhanced suitability for various women's health needs, but it reports no new clinical results.

This study found that the monophasic oral contraceptive ethinylestradiol/chlormadinone acetate was more effective in treating mild to moderate papulopustular acne in women than ethinylestradiol/levonorgestrel.

This study concluded that finasteride, cyproterone acetate, and flutamide were similarly effective at reducing hirsutism in women, though they acted through different mechanisms.

In this study, low doses of cyproterone acetate with ethinylestradiol were as effective as low-dose flutamide in reducing acne severity in hyperandrogenic women, while finasteride was less effective.

In this study, oral dienogest combined with ethinylestradiol provided effective contraception with a Pearl Index of approximately 0.2 and improved androgenic symptoms without significant metabolic effects.

This study found that both a high dose of CPA and GnRHa are effective for treating hirsutism in hyperandrogenic women, but GnRHa with add-back therapy may lead to a longer remission period.

This study found that the combined oral contraceptive containing ethinyl estradiol and chlormadinone acetate was effective in reducing moderate papulopustular acne and other androgen-related skin disorders compared to placebo.

This study found that women with androgenetic alopecia and alopecia areata had significantly lower serum ferritin levels compared to women without hair loss.

This review summarizes the use of chlormadinone acetate for hormone replacement therapy and contraception, highlighting its anti-androgenic effects, contraceptive efficacy, and clinical tolerability, without offering new clinical results.

This study found that in Chinese women with PCOS, pretreatment with ethinylestradiol/cyproterone acetate was associated with a lower risk of gestational diabetes, pregnancy-induced hypertension, and premature delivery compared to those without pretreatment.

A combined drug and laser treatment improved hirsutism in a PCOS patient, also enhancing her heart health and requiring regular liver and kidney checks.

This review discusses the use of ethinylestradiol combined with antiandrogenic progestin for treating androgenisation symptoms and improving metabolic and menstrual health in women, but it does not provide new clinical data.

This review evaluates therapies for hyperandrogenism, highlighting cyproterone acetate as the preferred treatment due to its potency and tolerability in managing symptoms in women.

This study found that cyproterone acetate significantly reduced both serum 3α-AdiolG levels and hirsutism scores in women with idiopathic hirsutism, PCOS, or 21-hydroxylase deficiency, suggesting its effectiveness in treating excessive hair growth.

This study observed a strong overall reduction in the use of CPA/EE in the Netherlands, despite similar proportions of users with acne or other hyperandrogenic conditions before and after the referral procedure.

This study concluded that intramuscular administration of medium-dose cyproterone acetate with oral ethinylestradiol is highly effective in managing hirsutism, showing better response rates than high-dose oral treatment.

This study found that androsterone glucuronate (ADT-G) was the only androgenic metabolite sensitive to detecting differences between adult women with acne and controls, and its levels decreased with systemic treatment.

This study found that treatment with cyproterone acetate and ethinylestradiol in hirsute women reduced testosterone and androstenedione levels, decreased hair growth, and increased cortisol levels without changing catecholamine excretion.

This article reviews the diagnosis and management of polycystic ovary syndrome, emphasizing lifestyle changes and treatment strategies, and reports no new clinical results.

In this study, hirsute women treated with cyproterone acetate and ethinyloestradiol experienced significant reductions in sebum secretion and hair growth after several months.

This study suggests that lower-dose ethinyl estradiol formulations and progestin-only contraceptives may offer safer options for managing PCOS in obese women due to minimal metabolic effects.

This study concluded that cyproterone acetate alone produced antiandrogenic effects on the female gerbil prostate, while ethinyloestradiol alone stimulated estrogenic activity, and their combination led to prostatic lesions.